Table 1. Baseline characteristics of the BCLC early stage HCC patients before and after propensity score matching.
| Characteristics | Crude cohort | PSM cohort | |||||||
|---|---|---|---|---|---|---|---|---|---|
| SHCC (n=1,481) | MHCC (n=67) | P value | ASD | SHCC (n=126) | MHCC (n=64) | P value | ASD | ||
| Sex | 0.054 | 0.275 | 1.000 | 0.030 | |||||
| Male | 1,240 (83.7%) | 62 (92.5%) | 117 (92.9%) | 59 (92.2%) | |||||
| Female | 241 (16.3%) | 5 (5.7%) | 9 (7.1%) | 5 (7.8%) | |||||
| Age, year | 51.99±10.62 | 52.99±9.74 | 0.371 | 0.098 | 53.17±8.27 | 53.16±9.92 | 0.994 | 0.024 | |
| TBIL, μmol/L | 16.25±23.86 | 15.60±7.96 | 0.507 | 0.036 | 15.67±8.47 | 15.62±8.12 | 0.601 | 0.002 | |
| TP, g/L | 73.89±5.71 | 73.72±5.79 | 0.817 | 0.029 | 72.94±5.72 | 73.62±5.76 | 0.306 | 0.113 | |
| ALB, g/L | 42.32±3.93 | 42.57±4.32 | 0.549 | 0.059 | 42.38±3.72 | 42.52±4.37 | 0.818 | 0.036 | |
| ALT, U/L | 42.79±31.70 | 44.86±30.12 | 0.240 | 0.067 | 42.98±32.49 | 40.03±18.33 | 0.507 | 0.105 | |
| AST, U/L | 40.83±28.14 | 34.06±15.15 | 0.185 | 0.300 | 35.49±21.19 | 33.40±15.12 | 0.790 | 0.109 | |
| GGT, U/L | 92.41±121.41 | 75.01±88.77 | 0.410 | 0.164 | 67.76±57.17 | 75.75±90.77 | 0.899 | 0.103 | |
| ALP, U/L | 93.21±56.84 | 81.48±31.36 | 0.039 | 0.256 | 80.13±32.08 | 82.11±31.90 | 0.747 | 0.060 | |
| AFP, ng/mL | 371.75±499.68 | 351.68±458.91 | 0.479 | 0.042 | 305.90±482.08 | 362.90±465.60 | 0.437 | 0.127 | |
| CA199, ng/mL | 28.72±56.97 | 24.55±24.68 | 0.977 | 0.095 | 24.28±22.13 | 24.93±24.98 | 0.750 | 0.039 | |
| WBC, 109/L | 5.30±1.77 | 4.94±1.37 | 0.108 | 0.229 | 5.08±1.69 | 4.99±1.37 | 0.910 | 0.063 | |
| RBC, 109/L | 4.66±0.52 | 4.66±0.49 | 0.652 | 0.001 | 4.71±0.46 | 4.67±0.50 | 0.527 | 0.097 | |
| PLT, 109/L | 162.20±70.06 | 135.25±51.56 | 0.004 | 0.437 | 139.30±68.83 | 136.72±51.29 | 0.744 | 0.062 | |
| INR | 1.00±0.08 | 1.02±0.10 | 0.058 | 0.269 | 1.02±0.09 | 1.02±0.10 | 0.987 | 0.050 | |
| PT, s | 12.01±0.97 | 12.29±1.16 | 0.057 | 0.267 | 12.25±1.03 | 12.29±1.18 | 0.987 | 0.043 | |
| HBV DNA load | 0.561 | 0.072 | 0.475 | 0.095 | |||||
| >103 IU/mL | 739 (49.9%) | 31 (46.3%) | 64 (50.8%) | 29 (45.3%) | |||||
| ≤103 IU/mL | 742 (50.1%) | 36 (53.7%) | 62 (49.2%) | 35 (54.7%) | |||||
| HBsAg | 0.290 | 0.143 | 0.974 | 0.000 | |||||
| Positive | 1,282 (86.6%) | 61 (91.0%) | 114 (90.5%) | 58 (90.6%) | |||||
| Negative | 199 (13.4%) | 6 (9.0%) | 12 (9.5%) | 6 (9.4%) | |||||
| HBsAb | 0.761 | 0.037 | 0.921 | 0.022 | |||||
| Positive | 223 (15.1%) | 11 (16.4%) | 19 (15.1%) | 10 (15.6%) | |||||
| Negative | 1,258 (84.9%) | 56 (83.6%) | 107 (84.9%) | 54 (84.4%) | |||||
| HBeAg | 0.211 | 0.153 | 0.715 | 0.034 | |||||
| Positive | 405 (27.3%) | 23 (34.3%) | 40 (31.7%) | 22 (34.4%) | |||||
| Negative | 1,076 (72.7%) | 44 (65.7%) | 86 (68.3%) | 42 (65.6%) | |||||
| HBeAb | 0.037 | 0.247 | 0.555 | 0.068 | |||||
| Positive | 1,137 (76.8%) | 44 (65.7%) | 88 (69.8%) | 42 (65.6%) | |||||
| Negative | 344 (23.2%) | 23 (34.3%) | 38 (30.2%) | 22 (34.4%) | |||||
| HBcAb | 0.622 | 0.182 | 1.000 | 0.126 | |||||
| Positive | 1,457 (98.4%) | 67 (100.0%) | 125 (99.2%) | 64 (100.0%) | |||||
| Negative | 24 (1.6%) | 0 (0.0%) | 1 (0.8%) | 0 (0.0%) | |||||
| Child-Pugh | 1.000 | 0.089 | 1.000 | 0.057 | |||||
| A | 1,440 (97.2%) | 66 (98.5%) | 123 (97.6%) | 63 (98.4%) | |||||
| B | 41 (2.8%) | 1 (1.5%) | 3 (2.4%) | 1 (1.6%) | |||||
| Pringle maneuver | 0.077 | 0.255 | 0.735 | 0.108 | |||||
| Yes | 1,282 (86.6%) | 63 (94.0%) | 121 (96.0%) | 60 (93.8%) | |||||
| No | 199 (13.4%) | 4 (6.0%) | 5 (4.0%) | 4 (6.3%) | |||||
| Transfusion | 0.155 | 0.191 | 0.777 | 0.049 | |||||
| Yes | 279 (18.8%) | 8 (11.9%) | 14 (11.1%) | 8 (12.5%) | |||||
| No | 1,202 (81.2%) | 59 (88.1%) | 112 (88.9%) | 56 (87.5%) | |||||
| Capsule | 0.011 | 0.351 | 0.651 | 0.063 | |||||
| Complete | 434 (29.3%) | 10 (14.9%) | 23 (18.3%) | 10 (15.6%) | |||||
| Incomplete | 1,047 (70.7%) | 57 (85.1%) | 103 (81.7%) | 54 (84.4%) | |||||
| Cirrhosis | 0.101 | 0.209 | 0.692 | 0.082 | |||||
| Yes | 777 (52.5%) | 42 (62.7%) | 75 (59.5%) | 40 (62.5%) | |||||
| No | 704 (47.5%) | 25 (37.3%) | 51 (40.5%) | 24 (37.5%) | |||||
| ES grade | 0.723 | 0.045 | 0.769 | 0.054 | |||||
| I-II | 391 (26.4%) | 19 (28.4%) | 31 (24.6%) | 17 (26.6%) | |||||
| III-IV | 1,090 (73.6%) | 48 (71.6%) | 95 (75.4%) | 47 (73.4%) | |||||
| MVI | 0.938 | 0.009 | 0.831 | 0.016 | |||||
| Yes | 656 (44.3%) | 30 (44.8%) | 57 (45.2%) | 30 (46.9%) | |||||
| No | 825 (55.7%) | 37 (55.2%) | 69 (54.8%) | 34 (53.1%) | |||||
| Diameter, cm | 5.37±3.68 | 2.40±0.46 | <0.001 | 1.131 | 4.33±2.88 | 2.41±0.47 | <0.001 | 0.932 | |
| Tumor number | NA | NA | |||||||
| 1 | 1,481 (100.0%) | 0 (0.0%) | 126 (100.0%) | 0 (0.0%) | |||||
| 2 | 0 (0.0%) | 62 (92.5%) | 0 (0.0%) | 60 (93.8%) | |||||
| 3 | 0 (0.0%) | 5 (7.5%) | 0 (0.0%) | 4 (6.3%) | |||||
| Location | NA | NA | |||||||
| Same lobe | 0 (0.0%) | 50 (74.6%) | 0 (0.0%) | 47 (73.4%) | |||||
| Different lobe | 0 (0.0%) | 17 (25.4%) | 0 (0.0%) | 17 (26.6%) | |||||
| Very early stage | NA | NA | |||||||
| Yes | 170 (11.5%) | 0 (0.0%) | 17 (13.5%) | 0 (0.0%) | |||||
| No | 1,311 (88.5%) | 0 (0.0%) | 109 (86.5%) | 0 (0.0%) | |||||
TBIL, total bilirubin; TP, total protein; ALB, albumin; ALT, alanine transaminase; AST, aspartate aminotransferase; GGT, γ-glutamyl transpeptidase; ALP, alkaline phosphatase; AFP, alpha fetal protein; CA199, carbohydrate antigen 19-9; WBC, white blood cells; RBC, red blood cells; PLT, platelets; INR, international normalized ratio; PT, prothrombin time; HBsAg, hepatitis B surface antigen; HBsAb, hepatitis B surface antibody; HBeAg, hepatitis B e antigen; HBeAb, hepatitis B e antibody; HBcAb, hepatitis B core antibody; ES, Edmondson-Steiner; MVI, microvascular invasion; NA, no answer; ASD, absolute standard difference.